On this page
BTK
Bruton tyrosine kinase
The BTK gene encodes Bruton tyrosine kinase, a protein vital for the normal development and function of B cells, which are key components of the immune system. The BTK gene provides instructions for producing the Bruton tyrosine kinase protein, essential for B cell development and maturation.
BTK is located on the long (q) arm of chromosome X, at band Xq22.1. Arm ratio per GRCh38 - banding schematic.
Explore chromosome X in the library →Available at Jeen Health
Clinical tests that include this
Overview
The BTK gene, or Bruton tyrosine kinase, plays a critical role in the human immune system. It provides the genetic blueprint for a protein that is fundamental to the development and function of B cells, a type of white blood cell responsible for producing antibodies. Proper BTK function is therefore essential for a robust immune response to infections.
Disruptions to the BTK gene can lead to a compromised immune system, making individuals more susceptible to various infections. Its importance is underscored by its association with conditions characterised by severe immunodeficiency.
What the gene does
The BTK protein functions as a tyrosine kinase, meaning it adds phosphate groups to specific tyrosine residues on other proteins, thereby acting as a crucial signalling molecule within cells. In B cells, BTK transmits important chemical signals that guide their maturation and instruct them to produce antibodies. These antibodies are specialised proteins that identify and neutralise foreign particles and pathogens.
Without a functional BTK protein, B cells cannot properly mature and differentiate into antibody-producing cells. This impairment directly affects the body's ability to mount an effective humoral immune response, leaving the individual vulnerable to recurrent infections. The protein's activity is central to the B cell receptor signalling pathway.
Video: Genetics 101
Chromosome location
The BTK gene is located on the long (q) arm of the X chromosome at position 22.1, specifically at Xq22.1. This chromosomal location means that conditions associated with BTK are typically inherited in an X-linked pattern.
Protein structure
The BTK protein consists of 659 amino acids and features several distinct domains critical for its function. It contains an N-terminal PH (Pleckstrin Homology) domain (amino acids 3-133), which includes an Inositol-(1,3,4,5)-tetrakisphosphate 1-binding region (amino acids 12-24). Following this is a Btk-type Zinc finger domain (amino acids 135-171) and a Disordered region (amino acids 171-210). Further downstream are the SH3 (Src Homology 3) domain (amino acids 214-274) and the SH2 (Src Homology 2) domain (amino acids 281-377). The catalytic activity resides within the Protein kinase domain (amino acids 402-655), which also contains a CAV1-binding motif (amino acids 581-588).
Key variants
Variants within the BTK gene can significantly impact its function, leading to various health conditions. Many of these variants can alter the protein's structure or reduce its expression, resulting in a non-functional or absent Bruton tyrosine kinase protein. Over 600 different BTK gene variants have been identified, with most leading to a lack of functional BTK protein.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1085A>G | p.His362Arg | Pathogenic | ★★☆☆ | BTK-related disorder |
c.182T>A | p.Ile61Asn | Pathogenic/Likely pathogenic | ★★☆☆ | X-linked agammaglobulinemia with growth hormone deficiency |
c.1834C>T | p.Gln612Ter | Pathogenic | ★★☆☆ | X-linked agammaglobulinemia |
c.1921C>T | p.Arg641Cys | Pathogenic/Likely pathogenic | ★★☆☆ | X-linked agammaglobulinemia with growth hormone deficiency |
c.423del | p.Lys141fs | Pathogenic | ★★☆☆ | X-linked agammaglobulinemia |
c.1300G>T | p.Glu434Ter | Pathogenic | ★☆☆☆ | X-linked agammaglobulinemia with growth hormone deficiency |
c.1428_1429del | p.Met477fs | Pathogenic | ★☆☆☆ | X-linked agammaglobulinemia with growth hormone deficiency |
c.1545del | p.Lys515fs | Pathogenic | ★☆☆☆ | X-linked agammaglobulinemia with growth hormone deficiency |
c.1574_1575dup | p.Asn526fs | Pathogenic | ★☆☆☆ | BTK-related disorder |
c.425dup | p.Tyr142Ter | Pathogenic | ★☆☆☆ | X-linked agammaglobulinemia with growth hormone deficiency |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Pathogenic variants in the BTK gene are primarily associated with X-linked agammaglobulinaemia (Bruton), an inherited immunodeficiency condition. This disorder is characterised by a severe reduction or absence of B cells and antibodies, leading to recurrent, severe infections. A few specific BTK variants have also been linked to Isolated growth hormone deficiency, which can result in slow growth, short stature, and a weakened immune system.
- X-linked agammaglobulinaemia Dedicated page coming soon
- X-linked agammaglobulinaemia (Bruton) Dedicated page coming soon
Inheritance pattern
Conditions caused by pathogenic BTK variants typically follow X-linked inheritance.
Carrier frequency by population How common is heterozygous BTK carrier status across ancestry groups?UK clinical status
The BTK gene is actively reviewed within the UK's NHS Genomic Medicine Service, featuring on several national testing panels. It holds a 'green' status on the Agammaglobulinaemia with absent BTK expression panel (R233), the COVID-19 research panel, the Infantile enterocolitis & monogenic inflammatory bowel disease panel, the Pituitary hormone deficiency panel (R159), and the Primary immunodeficiency or monogenic inflammatory bowel disease panel (R15).
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
What is the main function of the BTK gene?
The BTK gene provides instructions for making the Bruton tyrosine kinase protein, which is essential for the development and maturation of B cells. These B cells are crucial for producing antibodies that help the body fight off infections.
What condition is most commonly associated with BTK gene variants?
The condition most commonly associated with pathogenic BTK gene variants is X-linked agammaglobulinaemia (Bruton). This is an immunodeficiency disorder characterised by a lack of B cells and antibodies, making affected individuals highly susceptible to infections.
Why is the BTK gene considered important for the immune system?
The BTK gene is vital for the immune system because the protein it produces is a key signalling molecule within B cells. Without functional BTK, B cells cannot mature properly or produce antibodies, which are critical for an effective adaptive immune response against pathogens.
References
- Wit JM, Kiess W, Mullis P. Genetic evaluation of short stature. Best practice & research. Clinical endocrinology & metabolism. 2011. PMID: 21396571
- Alatzoglou KS, Dattani MT. Genetic causes and treatment of isolated growth hormone deficiency-an update. Nature reviews. Endocrinology. 2010. PMID: 20852587
- Jyonouchi H, Geng L, Törüner GA. Monozygous twins with a microdeletion syndrome involving BTK, DDP1, and two other genes; evidence of intact dendritic cell development and TLR responses. European journal of pediatrics. 2008. PMID: 17520285
- Conley ME, Farmer DM, Dobbs AK. A minimally hypomorphic mutation in Btk resulting in reduced B cell numbers but no clinical disease. Clinical and experimental immunology. 2008. PMID: 18241230
- Sedivá A, Smith CI, Asplund AC. Contiguous X-chromosome deletion syndrome encompassing the BTK, TIMM8A, TAF7L, and DRP2 genes. Journal of clinical immunology. 2007. PMID: 17851739
- Broides A, Yang W, Conley ME. Genotype/phenotype correlations in X-linked agammaglobulinemia. Clinical immunology (Orlando, Fla.). 2006. PMID: 16297664
- Väliaho J, Smith CI, Vihinen M. BTKbase: the mutation database for X-linked agammaglobulinemia. Human mutation. 2006. PMID: 16969761
- Richter D, Conley ME, Rohrer J. A contiguous deletion syndrome of X-linked agammaglobulinemia and sensorineural deafness. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2001. PMID: 11338284
- Maas A, Hendriks RW. Role of Bruton's tyrosine kinase in B cell development. Developmental immunology. 2001. PMID: 11785667
- Adam MP, Bick S, Mirzaa GM. X-Linked Agammaglobulinemia. 1993. PMID: 20301626